Skip to main content

Sagimet Biosciences Inc.

For the period ended Dec 31, 2025. Filed Mar 11, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 11, 2026

SGMT$10.83+9.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.

​SAGIMET BIOSCIENCES, INC.
​​
Date: March 11, 2026By:/s/ David Happel
​​David Happel
​​President and Chief Executive Officer
​​(Principal Executive Officer)
​​​
​​​
Date: March 11, 2026By:/s/ Thierry Chauche
​​Thierry Chauche
​​Chief Financial Officer
​​(Principal Financial and Accounting Officer)
​​​
​​​

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of David Happel and Thierry Chauche his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

​​​​​
Name​Title​Date
​​​​​
/s/ David Happel​President, Chief Executive Officer and Director​March 11, 2026
David Happel​(Principal Executive Officer)​​
​​​​​
/s/ Thierry Chauche​Chief Financial Officer​March 11, 2026
Thierry Chauche​(Principal Financial and Accounting Officer)​​
​​​​​
/s/ George Kemble, PhD​Chairman of the Board​March 11, 2026
George Kemble, PhD​​​​
​​​​​
/s/ Anne Phillips, MD​Director​March 11, 2026
Anne Phillips, MD​​​​
​​​​​
/s/ Beth Seidenberg, MD​Director​March 11, 2026
Beth Seidenberg, MD​​​​
​​​​​
/s/ Elizabeth Grammer, Esq.​Director​March 11, 2026
Elizabeth Grammer, Esq.​​​​
​​​​​
/s/ Jennifer Jarrett​Director​March 11, 2026
Jennifer Jarrett​​​​
​​​​​
/s/ Paul Hoelscher​Director​March 11, 2026
Paul Hoelscher​​​​
​​​​​
/s/ Tim Walbert​Director​March 11, 2026
Tim Walbert​​​​
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.